Royalty Pharma (RPRX) Expected to Announce Quarterly Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) will likely be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $1.27 per share and revenue of $758.9270 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The firm had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. On average, analysts expect Royalty Pharma to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $58.43 on Monday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The firm has a market cap of $33.65 billion, a price-to-earnings ratio of 39.75, a price-to-earnings-growth ratio of 10.35 and a beta of 0.43. The firm’s fifty day moving average price is $56.19 and its 200 day moving average price is $49.93. Royalty Pharma has a 1-year low of $34.08 and a 1-year high of $60.44.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, August 14th. Royalty Pharma’s payout ratio is 63.95%.

Analyst Ratings Changes

Several research analysts recently issued reports on RPRX shares. UBS Group increased their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Weiss Ratings lowered Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. Morgan Stanley increased their price objective on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Finally, JPMorgan Chase & Co. raised their target price on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $56.57.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, EVP Christopher Hite sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the completion of the transaction, the executive vice president directly owned 559,399 shares in the company, valued at approximately $30,431,305.60. This trade represents a 21.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of Royalty Pharma stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $52.75, for a total transaction of $721,831.00. Following the transaction, the executive vice president owned 18,197 shares of the company’s stock, valued at approximately $959,891.75. The trade was a 42.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 393,009 shares of company stock valued at $21,601,827. Company insiders own 18.84% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada increased its position in Royalty Pharma by 367.7% during the first quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock worth $6,342,000 after buying an additional 160,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Royalty Pharma by 20.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock valued at $2,490,000 after acquiring an additional 13,489 shares in the last quarter. Focus Partners Wealth acquired a new stake in shares of Royalty Pharma during the first quarter valued at $264,000. Intech Investment Management LLC increased its position in Royalty Pharma by 41.0% during the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock worth $1,494,000 after purchasing an additional 13,951 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Royalty Pharma by 21.4% in the 2nd quarter. Invesco Ltd. now owns 1,559,378 shares of the biopharmaceutical company’s stock valued at $56,184,000 after purchasing an additional 274,960 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.